Insider Buying: Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Acquires 9,906 Shares of Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. acquired 9,906 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were purchased at an average cost of $24.46 per share, for a total transaction of $242,300.76. Following the acquisition, the insider directly owned 6,324,431 shares in the company, valued at $154,695,582.26. This represents a 0.16% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.81 per share, for a total transaction of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.98 per share, for a total transaction of $37,045.34.
• On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.60 per share, for a total transaction of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. acquired 97,411 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $24.63 per share, for a total transaction of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Price Performance

Shares of NASDAQ:COAG traded down $0.12 during trading on Monday, hitting $25.00. 239,335 shares of the stock were exchanged, compared to its average volume of 376,423. Hemab Therapeutics Holdings, Inc. has a 1-year low of $23.00 and a 1-year high of $36.61.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research report on Saturday.